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Background:  Severe focal vasoconstriction during administration of intravenous ergonovine (Erg) is indicative of coronary vasospasm. We 
hypothesized that outcomes of patients with intermediate response to Erg are similar to those with severe vasoconstriction.
methods:  From 2005-2010, 1,178 consecutive patients suspected of having vasospasm underwent Erg coronary angiography (CAG). 
Angiographic CAD was defined as ≥40% visual diameter stenosis. MACE (cardiac death, MI and revascularization) was evaluated in three 
groups according to result of ErgCAG: 1) Negative (<50% spasm) [n=719]; 2) Intermediate (50-74% spasm) [n=156]; 3) Positive (≥75% 
spasm) [n=303].
results:  Mean age was 55±11 years, 64% were men, 52% had atypical chest pain, 30% variant angina, 14% unstable angina, and 4% 
had MI. Majority of patients (91%) had no significant CAD. Compared to Group 1, patients in Groups 2 and 3 were more likely to be male 
(OR 2.5; 95% CI 1.8- 3.5, p<0.001) and have hypertension (OR 2.2; 95% CI 1.6 -2.8, p<0.001). Interestingly among patients in Groups 
2 and 3, the incidence of multivessel spasm was greater (43% vs 28%, p<0.01) and angiographic CAD less (10% vs 23%, p=0.001) for 
those in Group 2 compared with Group 3. There were no differences in statin use. At a median follow up of 28 months (range 2-65 months) 
there were no significant differences in MACE between groups 1, 2, and 3 (1.8%, 2.6%, 4.6%, respectively, p=NS). Cox regression survival 
analyses demonstrated that among various clinical and angiographic variables, only significant angiographic stenosis was an independent 
predictor of MACE (odd ratio 4.1; 95% CI 2.0 - 8.7; p < 0.001).
Conclusion:  Long term outcomes of patients with suspected coronary vasospasm are favorable in all three ergonovine response groups. 
The only independent predictor of MACE is significant angiographic CAD.
